Text resize

COUNTRY

ASPREE AUS

Phone Icon

1800 728 745

ASPirin in Reducing Events in the Elderly 
FOR PARTICIPANTS
FOR RESEARCHERS
FOR CLINICIANS

A letter from ASPREE PI, Professor John McNeil, to Australian participants and GPs

Dec 4, 2014

To our ASPREE participants and GP Associate Investigators,

 

The ASPREE team sincerely thanks you for supporting the ASPREE study. Without your ongoing support for medical research, this significant trial would not be possible.

For the next three years, ASPREE will be in the ‘observational’ stage until the trial concludes in 2017.

This three year period is critical to determine the findings of the study.

Above: ASPREE Principal Investigator in Australia, Prof John McNeil, penned an open letter to 16,500 Australian ASPREE trial participants and their GPs as the trial moves from recruitment to the next phase.

What participation in the ‘observation’ stage of the trial will involve:

  • We ask ASPREE participants to please continue to take your daily study medication and attend annual study visits with our research staff.
  • Even if participants have to come off study medication on the advice of a doctor, we hope to see you at annual study visits. You are still very important to this study!
  • We will endeavour to call our participants approximately every 3 months between annual visits to see how you are.
  • If a participant finds it difficult to attend a study visit, there are a number of options we can discuss to make follow-up easier for you.

With the help of ASPREE participants and GP Associate Investigators over the next 3 years, we will learn about changes in health with and without aspirin. For this, we thank you.

If you have a question about the study please go to our FAQs on the website or feel free to contact the ASPREE team on 1800 728 745 (toll free from a landline). View the open letter from Prof. McNeil here.

Updated 22.03.2021

 

Other Articles

CliniciansA letter from ASPREE PI, Professor John McNeil, to Australian participants and GPs